PERBEDAAN KADAR PSA DAN TGF-β1 TERHADAP PEMBERIAN KOMBINASI INHIBITOR 5α-REDUKTASE (DUTASTERIDE) DAN ANTI ESTROGEN (TAMOXIFEN) PADA PASIEN BPH LUTS

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

PDF
Rachmat Budi Prasetyo Soetojo Soetojo Doddy M Soebadi

Abstract

Objective: To compare the PSA and TGF-β1 plasma level before and after administration of a 5α-reductase inhibitor (dutasteride) and an anti estrogen (tamoxifen) in nonobstructive patients with BPH. Material and Method: We enrolled 40 patients with a diagnosis of BPH without urinary retention. Patients were allocated into 4 groups of 10 patients and were given tamoxifen, dutasteride, a combination of tamoxifen and dutasteride, or placebo. We measured PSA and TGF-β1 plasma levels at study entry and 3 months after administration. Data were analysed using SPSS 12. Results: Increase of TGF-β1, as high as 54% (2,18 ± 0,88 to 3,36 ± 1,06) in the tamoxifen group, 26% (2,75 ± 0,62 to 3,47 ± 0,82) in the dutasteride group, and 92% (2,37 ± 0,75 to 4,56 ± 1,98) in the combination group, was significant (p < 0,05). PSA was not significantly decreased in all groups (p > 0,05). PSA decreased 28% (4,25 ± 3,28 to 3,06 ± 3,08) in the tamoxifen group, 27% (2,20 ± 2,17 to 1,60 ± 0, 982) in the dutasteride group, and 19% (2,95 ± 1,22 to 2,40 ± 1,78) in the combination group. In the placebo group was no significant difference of both parameters. Conclusion: TGF-β1 was significantly increased in all groups except in placebo. PSA was decreased in all groups but not significant statistically. We concluded that TGF-β1 may better be used as a biomarker in the evaluation and management of BPH than PSA.


##plugins.themes.bootstrap3.article.details##

Keywords

PSA, TGF-β1, tamoxifen, dutasteride

References

Presti JC Jr. Neoplasm of the prostat gland. In: Tanagho EA, Mc Anich JW, ed. Smith’s General Urology, 15th ed. International edition. Mc Graw Hill; 2000. p. 399 – 417.

Jones DA. Benign prostatic hypertrophy and lower urinary tract dysfunction. In: Weis MR, George N Jr., O’Reilly PH, ed. Comprehensive Urology. London: Mosby; 2001. p. 451 – 63.

Kirby RS, Fitzpatrick A. Shared care for prostatic diseases. MSD. Oxford; 1994. p. 37 – 42.

Rahardjo D. Prostat. Edisi 1. Asian Medical. Jakarta; 1999. p. 10 – 11.

Prasetyo RB, Soetojo. Analisis flowmetri pada penderita BPH non obstruktif yang dilakukan TUR-P. Studi Analitik Retrospektif dari Penderita yang Dirawat di RSU Dr. Soetomo Surabaya periode tahun 2005. Surabaya; 2006. p. 1 – 29.

n’Ancona FCH, Francisca EAE. Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0). The Journal of Urology 1997; 158: 1839 – 44.

Claus GR, Fiona C. The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters. The Journal of Urology 1999; 162: 92 – 7.

Clark RV, Hermann DJ. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasi by dutasteride a dual 5α-reductase inhibitor. The Journal Clinical Endokrinology and Metabolism 2004; 89 (5): 2179 – 84.

Seppelt U. Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy. Journal of Clinical Endocrinology & Metabolism 1978; 47: 1230 – 5 (Abstract).

Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross talk between transforming growth factor-beta and estrogen receptor signaling through smas-3. Department of Immunology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. J Biol Chem 2001; 276 (46): 42908 – 14.

Story MT. Regulation of prostat growth by fibroblast growth factors. World Journal of Urology 1995; 13 (5): 297 – 305.

Mc Connell JD, Roehrborn CG. Etiology, pathophysiology, and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein A ed. Campbell’s Urology, 8th ed. Philadelphia: WB Saunders; 2002. p. 1297 – 330.

Griffiths, Denis LJ, Turkes A. Oestrogens, phyto-oestrogens, and the pathogenesis of prostatic disease. 2002. p. 67 – 158.

Soetojo. Pengaruh pemberian kombinasi inhibitor 5α-reduktase dan estrogen pada proliferasi jaringan prostat. Surabaya; 2004. p. 1 – 169.

Nugroho E, Soetojo. Perbandingan kadar estrogen dalam serum dan TGF-β1 dalam plasma pada penderita BPH – non BPH di atas 50 tahun, dan usia muda. Surabaya; 2006. p. 1 – 72.

DiSilverio F, Sciarra A, Monti S. Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostat specific antigen levels in patients with benign prostatic hyperplasia? Journal of Urology 1999; 161: 128 – 32.

Price CP, Allard J, Davies G. Pre and post analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001; 38: 188 – 216.

Tobing M, Endang R, Soetojo. Hubungan antara kadar TGF-β1 dengan PSA plasma pada penderita BPH dan non BPH di RSU Dr. Soetomo. 2006. p. 45 – 61.

Habib FK, Rafati G, Robinson MR, Stitch SR. Effects of tamoxifen on the binding and metabolism of testosterone by human prostatic tissue and plasma in vitro. Journal of Endocrinology 1979; 83 (3): 369 – 78.

DiSilverio F, D'Eramo G, Flamina GP, Buscarini M, Frascaro E, Mariani M, et al. Pharmacological combinations in the treatment of benign prostatic hypertrophy. France. Journal of Urology 1993; 99 (6): 316 – 20. Droeller MJ. Medical approach in the management of prostatic disease. British Journal of Urology 1997; 79 (2): 42 – 52.

Atif MN, Nicholas AR, William R. Estradiol activates the prostate androgen Receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. American Society of Biochewmistry and Molecular Biology 1997; 272 (11): 6838 – 41.

Regina O, Michael M, Ramzan I. Drug-metabolizing enzymes and transporters: Expression in the human prostate and roles in prostate drug disposition. Journal of Andrology; 2006: 27 (2).

Wolff JM, Fandel T, Borchers H, Bremer B Jr, Jakse G. Transforming growth factor-beta 1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. British Journal of Urology 1998; 81 (3): 403 – 5.

Guilliams TG. BPH: The natural approach. The Standard. April 1998; 1 (1): 1 – 4.

McConnell JD. Prostatic growth: New insights into hormonal regulation. British Journal of Urology 1995. p. 76 – 9.

Section
Articles
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University